-
TRANSLATION AND PSYCHOMETRIC EVALUATION OF THE YORUBA VERSION OF IBADAN LOW-BACK PAIN DISABILITY QUESTIONNAIRE
Mar 18, 2026, 21:38 PM -
BRIDGING HER2 TESTING AND TREATMENT: REAL-WORLD EVIDENCE ACROSS 22 SOLID TUMORS
Mar 18, 2026, 21:38 PM -
NEUROLOGIST PREFERENCES FOR NEW MS TREATMENTS: IMPLICATIONS FOR MARKET ACCESS PRIORITIZATION IN THE UNITED STATES AND EUROPE
Mar 18, 2026, 21:38 PM -
FORMULARY EXCLUSIONS AND NON-ADHERENCE TO DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS IN MEDICARE PART D
Mar 18, 2026, 21:38 PM -
MEASURING ADHERENCE TO, AND PERSISTENCE WITH, ADVANCED THERAPY IN PATIENTS WITH LUPUS NEPHRITIS IN THE REAL-WORLD SETTING
Mar 18, 2026, 21:38 PM -
CAREGIVER PRODUCTIVITY LOSS AND HEALTH-RELATED QUALITY OF LIFE ASSOCIATED WITH PEDIATRIC RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREA
Mar 18, 2026, 21:38 PM -
DISABILITY AND ADHERENCE TO GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS AMONG U.S. ADULTS WITH DIABETES: EVIDENCE FROM THE MEDICAL EXPENDITURE PANEL SURVEY
Mar 18, 2026, 21:38 PM -
USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS
Mar 18, 2026, 21:38 PM -
INCORPORATING REAL-WORLD EVIDENCE (RWE) USING A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) AUGMENTS TRADITIONAL SLRS: CASE STUDY IN NON-SMALL-CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
INTERPRETABLE MACHINE LEARNING TO PREDICT CATASTROPHIC HEALTH EXPENDITURE RISK IN CHINA: EVIDENCE FROM NATIONALLY REPRESENTATIVE SURVEY DATA
Mar 18, 2026, 21:38 PM -
SAFETY OF SEPIAPTERIN AND PEGVALIASE FOR THE TREATMENT OF PHENYLKETONURIA (PKU): A SIMULATED TREATMENT COMPARISON (STC)
Mar 18, 2026, 21:38 PM -
COMPARATIVE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN
Mar 18, 2026, 21:38 PM -
NATURAL HISTORY, MANAGEMENT, AND BURDEN OF DISEASE IN ADULTS WITH NF1 AND SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN FRANCE
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE HEALTH-RELATED QUALITY OF LIFE BURDEN IN CHRONIC HEPATITIS DELTA INFECTION: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
COST OF CARE AND BUDGET IMPACT OF FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FROM THE MEXICAN PUBLIC PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
CONCEPTUAL COST-EFFECTIVENESS FRAMEWORK FOR GMRX2 (TELMISARTAN/AMLODIPINE/INDAPAMIDE) AS EARLY COMBINATION THERAPY FOR US ADULTS WITH HYPERTENSION WITHOUT MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, USED EITHER AT INITIATION OR AS A STEP-UP FROM...
Mar 18, 2026, 21:38 PM -
COMPARING THE DISEASE BURDEN OF MIGRAINE BETWEEN USERS OF CGRP MONOCLONAL ANTIBODIES AND PREVENTIVE GEPANTS
Mar 18, 2026, 21:38 PM -
ESTIMATING THE FINANCIAL IMPACT OF DUPILUMAB FOR COPD USING REAL-WORLD CLAIMS DATA: A PROBABILISTIC BUDGET IMPACT ANALYSIS IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
FROM PROMPT ENGINEERING TO DECISION-MAKING: ARTIFICIAL INTELLIGENCE IN HEALTH TECHNOLOGY ASSESSMENT
Mar 18, 2026, 21:38 PM
